291 related articles for article (PubMed ID: 15364688)
21. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
Stong BC; DelGaudio JM; Hapner ER; Johns MM
Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
[TBL] [Abstract][Full Text] [Related]
22. Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
Anari S; Carding PN; Hawthorne MR; Deakin J; Drinnan MJ
Laryngoscope; 2007 Oct; 117(10):1888-92. PubMed ID: 17690610
[TBL] [Abstract][Full Text] [Related]
23. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
24. A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor.
Van Der Walt A; Sung S; Spelman T; Marriott M; Kolbe S; Mitchell P; Evans A; Butzkueven H
Neurology; 2012 Jul; 79(1):92-9. PubMed ID: 22753445
[TBL] [Abstract][Full Text] [Related]
25. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
26. [Botulinum toxin efficacy in the treatment of patients with spasmodic dysphonia].
Svetel M; Vasić M; Tomić G; Stanković P; Stojanović M; Dragasević N; Dergenc R; Vukasinović M; Pekmezović T; Petrović I; Kostić V
Vojnosanit Pregl; 2007 Oct; 64(10):671-5. PubMed ID: 18041568
[TBL] [Abstract][Full Text] [Related]
27. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection.
Warrick P; Dromey C; Irish JC; Durkin L; Pakiam A; Lang A
Laryngoscope; 2000 Aug; 110(8):1366-74. PubMed ID: 10942143
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
29. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia.
Klein AM; Stong BC; Wise J; DelGaudio JM; Hapner ER; Johns MM
Otolaryngol Head Neck Surg; 2008 Sep; 139(3):421-3. PubMed ID: 18722224
[TBL] [Abstract][Full Text] [Related]
30. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
[TBL] [Abstract][Full Text] [Related]
31. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
Mendelsohn AH; Berke GS
Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
[TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
Casserly P; Timon C
J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of botulinum toxin in primary orthostatic tremor.
Bertram K; Sirisena D; Cowey M; Hill A; Williams DR
J Clin Neurosci; 2013 Nov; 20(11):1503-5. PubMed ID: 23931935
[TBL] [Abstract][Full Text] [Related]
34. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
Adams SG; Hunt EJ; Charles DA; Lang AE
J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
[TBL] [Abstract][Full Text] [Related]
35. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
36. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia.
Chang CY; Chabot P; Thomas JP
Otolaryngol Head Neck Surg; 2007 Jun; 136(6):894-9. PubMed ID: 17547976
[TBL] [Abstract][Full Text] [Related]
37. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
Lerner MZ; Lerner BA; Patel AA; Blitzer A
Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
[TBL] [Abstract][Full Text] [Related]
38. Botulinum toxin therapy for abductor spasmodic dysphonia.
Woodson G; Hochstetler H; Murry T
J Voice; 2006 Mar; 20(1):137-43. PubMed ID: 16126369
[TBL] [Abstract][Full Text] [Related]
39. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
